Ethamsylate is believed to correct abnormal platelet adhesion, so reducing capillary bleeding.
It is licensed in short courses for reducing menorrhagia and also for the prophylaxis and treatment of periventricular haemorrhage in low birth weight infants.
It is contra-indicated in porphyria and may cause nausea, headaches and rashes.
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page